Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CD19 CAR-T cells CABA-201

A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the B-lymphocyte antigen CD19, coupled to a costimulatory domain of 4-1BB (CD137), with potential immunomodulatory activity. Upon administration, autologous anti-CD19 CAR-T cells CABA-201 target and bind to CD19-expressing B cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing B cells. CD19, a B-cell-specific cell surface antigen that plays an important role in B-cell activation, is overexpressed in some autoimmune diseases.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-CD19 CAR T cells CABA-201
autologous CD19-specific chimeric antigen receptor T cells CABA-201
Code name:CABA 201
CABA-201
CABA201
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search